Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
77
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic

      research-article
      1 , 2 , 3 , 4 , 5 , 6 , 7 , 4 , 5 , 8 , 2 , 3 , 3 , 3 , 4 , 5 , 3 , 9 , 10 , 11 , 11 , 11 , 12 , 4 , 5 , 4 , 5 , 4 , 13 , 3 , 14 , 15 , 16 , 17 , 18 , 19 , 18 , 14 , 15 , 9 , 18 , 2 , 1 , 16 , 18 , , 1 ,
      Science (New York, N.y.)
      American Association for the Advancement of Science

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Attack rate in Manaus

          Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked in Manaus, Brazil, in May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors from Manaus and São Paulo, noted when transmission began to fall, and estimated the final attack rates in October 2020 (see the Perspective by Sridhar and Gurdasani). Heterogeneities in immune protection, population structure, poverty, modes of public transport, and uneven adoption of nonpharmaceutical interventions mean that despite a high attack rate, herd immunity may not have been achieved. This unfortunate city has become a sentinel for how natural population immunity could influence future transmission. Events in Manaus reveal what tragedy and harm to society can unfold if this virus is left to run its course.

          Science, this issue p. 288; see also p. [Related article:]230

          Abstract

          The spread of COVID-19 in Manaus, Brazil, shows that a largely unmitigated epidemic can infect a high fraction of the population and cause high mortality.

          Abstract

          Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly in Manaus, the capital of Amazonas state in northern Brazil. The attack rate there is an estimate of the final size of the largely unmitigated epidemic that occurred in Manaus. We use a convenience sample of blood donors to show that by June 2020, 1 month after the epidemic peak in Manaus, 44% of the population had detectable immunoglobulin G (IgG) antibodies. Correcting for cases without a detectable antibody response and for antibody waning, we estimate a 66% attack rate in June, rising to 76% in October. This is higher than in São Paulo, in southeastern Brazil, where the estimated attack rate in October was 29%. These results confirm that when poorly controlled, COVID-19 can infect a large proportion of the population, causing high mortality.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Estimates of the severity of coronavirus disease 2019: a model-based analysis

          Summary Background In the face of rapidly changing data, a range of case fatality ratio estimates for coronavirus disease 2019 (COVID-19) have been produced that differ substantially in magnitude. We aimed to provide robust estimates, accounting for censoring and ascertainment biases. Methods We collected individual-case data for patients who died from COVID-19 in Hubei, mainland China (reported by national and provincial health commissions to Feb 8, 2020), and for cases outside of mainland China (from government or ministry of health websites and media reports for 37 countries, as well as Hong Kong and Macau, until Feb 25, 2020). These individual-case data were used to estimate the time between onset of symptoms and outcome (death or discharge from hospital). We next obtained age-stratified estimates of the case fatality ratio by relating the aggregate distribution of cases to the observed cumulative deaths in China, assuming a constant attack rate by age and adjusting for demography and age-based and location-based under-ascertainment. We also estimated the case fatality ratio from individual line-list data on 1334 cases identified outside of mainland China. Using data on the prevalence of PCR-confirmed cases in international residents repatriated from China, we obtained age-stratified estimates of the infection fatality ratio. Furthermore, data on age-stratified severity in a subset of 3665 cases from China were used to estimate the proportion of infected individuals who are likely to require hospitalisation. Findings Using data on 24 deaths that occurred in mainland China and 165 recoveries outside of China, we estimated the mean duration from onset of symptoms to death to be 17·8 days (95% credible interval [CrI] 16·9–19·2) and to hospital discharge to be 24·7 days (22·9–28·1). In all laboratory confirmed and clinically diagnosed cases from mainland China (n=70 117), we estimated a crude case fatality ratio (adjusted for censoring) of 3·67% (95% CrI 3·56–3·80). However, after further adjusting for demography and under-ascertainment, we obtained a best estimate of the case fatality ratio in China of 1·38% (1·23–1·53), with substantially higher ratios in older age groups (0·32% [0·27–0·38] in those aged <60 years vs 6·4% [5·7–7·2] in those aged ≥60 years), up to 13·4% (11·2–15·9) in those aged 80 years or older. Estimates of case fatality ratio from international cases stratified by age were consistent with those from China (parametric estimate 1·4% [0·4–3·5] in those aged <60 years [n=360] and 4·5% [1·8–11·1] in those aged ≥60 years [n=151]). Our estimated overall infection fatality ratio for China was 0·66% (0·39–1·33), with an increasing profile with age. Similarly, estimates of the proportion of infected individuals likely to be hospitalised increased with age up to a maximum of 18·4% (11·0–7·6) in those aged 80 years or older. Interpretation These early estimates give an indication of the fatality ratio across the spectrum of COVID-19 disease and show a strong age gradient in risk of death. Funding UK Medical Research Council.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

            The clinical features and immune responses of asymptomatic individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been well described. We studied 37 asymptomatic individuals in the Wanzhou District who were diagnosed with RT-PCR-confirmed SARS-CoV-2 infections but without any relevant clinical symptoms in the preceding 14 d and during hospitalization. Asymptomatic individuals were admitted to the government-designated Wanzhou People's Hospital for centralized isolation in accordance with policy1. The median duration of viral shedding in the asymptomatic group was 19 d (interquartile range (IQR), 15-26 d). The asymptomatic group had a significantly longer duration of viral shedding than the symptomatic group (log-rank P = 0.028). The virus-specific IgG levels in the asymptomatic group (median S/CO, 3.4; IQR, 1.6-10.7) were significantly lower (P = 0.005) relative to the symptomatic group (median S/CO, 20.5; IQR, 5.8-38.2) in the acute phase. Of asymptomatic individuals, 93.3% (28/30) and 81.1% (30/37) had reduction in IgG and neutralizing antibody levels, respectively, during the early convalescent phase, as compared to 96.8% (30/31) and 62.2% (23/37) of symptomatic patients. Forty percent of asymptomatic individuals became seronegative and 12.9% of the symptomatic group became negative for IgG in the early convalescent phase. In addition, asymptomatic individuals exhibited lower levels of 18 pro- and anti-inflammatory cytokines. These data suggest that asymptomatic individuals had a weaker immune response to SARS-CoV-2 infection. The reduction in IgG and neutralizing antibody levels in the early convalescent phase might have implications for immunity strategy and serological surveys.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020

              On 5 February 2020, in Yokohama, Japan, a cruise ship hosting 3,711 people underwent a 2-week quarantine after a former passenger was found with COVID-19 post-disembarking. As at 20 February, 634 persons on board tested positive for the causative virus. We conducted statistical modelling to derive the delay-adjusted asymptomatic proportion of infections, along with the infections’ timeline. The estimated asymptomatic proportion was 17.9% (95% credible interval (CrI): 15.5–20.2%). Most infections occurred before the quarantine start.
                Bookmark

                Author and article information

                Journal
                Science
                Science
                SCIENCE
                science
                Science (New York, N.y.)
                American Association for the Advancement of Science
                0036-8075
                1095-9203
                15 January 2021
                08 December 2020
                : 371
                : 6526
                : 288-292
                Affiliations
                [1 ]Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
                [2 ]Departamento de Engenharia de Sistemas Eletrônicos, Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil.
                [3 ]Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil.
                [4 ]Fundação Pró-Sangue–Hemocentro de São Paulo, São Paulo, Brazil.
                [5 ]Laboratório de Investigação Médica em Patogênese e Terapia dirigida em Onco-Imuno-Hematologia (LIM-31), Departamento de Hematologia, Hospital das Clínicas HCFMUSP, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
                [6 ]Fundação Hemominas–Fundação Centro de Hematologia e Hemoterapia de Minas Gerais, Belo Horizonte, Brazil.
                [7 ]Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil.
                [8 ]Department of Virology and Experimental Therapy, Institute Aggeu Magalhaes, Oswaldo Cruz Foundation, Recife, Brazil.
                [9 ]Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
                [10 ]Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.
                [11 ]Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.
                [12 ]Center of Mathematics, Computing and Cognition–Universidade Federal do ABC, São Paulo, Brazil.
                [13 ]Oxford School of Global and Area Studies, Latin American Centre, University of Oxford, Oxford, UK.
                [14 ]Vitalant Research Institute, San Francisco, CA, USA.
                [15 ]University of California, San Francisco, CA, USA.
                [16 ]MRC Centre for Global Infectious Disease Analysis, J-IDEA, Imperial College London, London, UK.
                [17 ]Instituto Gonçalo Moniz–Fundação Oswaldo Cruz (Fiocruz), Salvador, Brazil.
                [18 ]Department of Zoology, University of Oxford, Oxford, UK.
                [19 ]Institute for Applied Economic Research–Ipea, Brasília, Brazil.
                Author notes
                [*]

                These authors contributed equally to this work.

                []Corresponding author. Email: sabinoec@ 123456usp.br (E.C.S.); nfaria@ 123456ic.ac.uk (N.R.F.)
                Author information
                https://orcid.org/0000-0002-9009-9301
                https://orcid.org/0000-0002-3907-423X
                https://orcid.org/0000-0001-9597-9618
                https://orcid.org/0000-0002-3090-4575
                https://orcid.org/0000-0002-8123-3118
                https://orcid.org/0000-0002-8490-4634
                https://orcid.org/0000-0002-1846-6007
                https://orcid.org/0000-0001-5595-8775
                https://orcid.org/0000-0002-3750-8110
                https://orcid.org/0000-0002-7312-6822
                https://orcid.org/0000-0002-8553-8699
                https://orcid.org/0000-0002-4190-0238
                https://orcid.org/0000-0001-9210-3661
                https://orcid.org/0000-0002-5003-2575
                https://orcid.org/0000-0003-2358-3221
                https://orcid.org/0000-0003-2416-1864
                https://orcid.org/0000-0002-0623-1999
                https://orcid.org/0000-0003-0094-619X
                https://orcid.org/0000-0001-7580-4597
                https://orcid.org/0000-0003-3585-8683
                https://orcid.org/0000-0002-4733-170X
                https://orcid.org/0000-0001-6251-366X
                https://orcid.org/0000-0002-7806-3605
                https://orcid.org/0000-0002-5823-7903
                https://orcid.org/0000-0001-8838-7147
                https://orcid.org/0000-0003-2125-7465
                https://orcid.org/0000-0002-8797-2667
                https://orcid.org/0000-0002-1446-125X
                https://orcid.org/0000-0003-4606-2795
                https://orcid.org/0000-0002-2957-1793
                https://orcid.org/0000-0002-0543-4735
                https://orcid.org/0000-0001-8839-2798
                https://orcid.org/0000-0003-2623-5126
                Article
                abe9728
                10.1126/science.abe9728
                7857406
                33293339
                64a3712c-c505-48e2-bda6-cfff3c2ff14d
                Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

                This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 28 September 2020
                : 02 December 2020
                Funding
                Funded by: doi http://dx.doi.org/10.13039/501100000265, Medical Research Council;
                Award ID: MR/S0195/1
                Funded by: Fundação de Amparo à Pesquisa do Estado de São Paulo;
                Award ID: 18/14389-0
                Funded by: Itau Unibanco Todos pela Saude;
                Categories
                Report
                Reports
                Reports
                Medicine
                Virology
                Custom metadata
                Caroline Ash
                Jeff Cook

                Uncategorized
                Uncategorized

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content218

                Cited by242

                Most referenced authors1,325